Pharmaceutical IP Law in India 2026: Key Patent and Trademark Developments

What are the key pharmaceutical IP developments in India in 2026?

Quick Answer:

The developments in Q3 and Q4 of 2026 produced three material shifts in India’s pharmaceutical IP framework. The Delhi High Court’s ruling in Array BioPharma Inc v Deputy Controller of Patents and Designs (23 July 2026, 2026:DHC:5856) clarified that Section 3(d) does not apply to combinations of independent active pharmaceutical ingredients, that a combination patent will not automatically be rejected as a “method of treatment” under Section 3(i) merely because the claim references sequential administration, and that Controllers invoking Section 3(d) must identify the “known compound” of which the claimed invention is allegedly a derivative.

The Supreme Court is examining a constitutional challenge to the 20-year patent term calculated from the filing date rather than the grant date (notice issued in Gunjan Sinha v Union of India in 2026 by Justices Pamidighantam Sri Narasimha and Alok Aradhe) — the outcome will shape the effective life of every Indian pharma patent. And Indian trademark enforcement in the pharma sector has sharpened around the heightened-caution line, with both Nava Healthcare v Antex Pharma (Delhi HC, 24 July 2026) and the Hahnemann DIGESTO PLUS Division Bench ruling (early September 2026) reinforcing when deceptive similarity will and will not sustain injunctive relief.

For foreign pharma counsel advising on India-facing matters, the practical consequence is that patent prosecution, trademark enforcement, and the pending patent term question all require fresh audit heading into the Q1 2027 cycle.

Why this matters for foreign pharma counsel

For foreign pharma counsel advising Big Pharma clients, biosimilar developers, patent applicants in India’s Patent Office, and foreign pharma brand owners managing Indian trademark portfolios, India’s Q3-Q4 2026 developments move the operational baseline in three directions. First, Section 3(d) is being applied with sharper evidentiary discipline — refusals are being set aside where the Controller has failed to analyse the enhanced therapeutic efficacy point.

Second, the enforceable patent term is itself under constitutional scrutiny — if the Supreme Court strikes down the filing-date calculation, foreign patent-holders whose Indian grants were materially delayed may obtain extended effective protection. Third, pharma trademark enforcement operates under a heightened-caution line that distinguishes genuinely deceptive similarity from descriptive-term overlap.

Together, these three shifts determine whether a foreign pharma company’s Indian patent will stand, when it will expire, and whether its Indian brand will attract enforcement.

The six sections below cover each development with the specific citations foreign counsel should reference.

Section 1: How has the Delhi High Court clarified Section 3(d) and Section 3(i) for pharmaceutical combination patents?

Bottom line. The Delhi High Court’s ruling in Array BioPharma Inc v Deputy Controller of Patents and Designs (23 July 2026, neutral citation 2026:DHC:5856, Case No. C.A. (COMM.IPD-PAT) 37/2023) is a significant decision concerning Indian pharmaceutical patent law, with important implications for patent prosecution for foreign pharma counsel. The Court held three things that materially affect pharmaceutical combination patent prosecution: Section 3(d) of the Patents Act, 1970 (the provision governing new forms of a known substance) does not apply to combinations of independent active pharmaceutical ingredients; Section 3(i) (the method-of-treatment exclusion) does not automatically defeat a combination claim merely because the claim references sequential administration; and where Section 3(d) is actually invoked, the Controller must specifically identify the “known compound” of which the claimed invention is allegedly a derivative. The Court set aside the Controller’s refusal and remanded the application for fresh consideration within six months.

The Array BioPharma ruling (23 July 2026). The application concerned a pharmaceutical combination for cancer therapy. The Deputy Controller had refused the application on three grounds — Section 3(d), Section 3(i), and lack of inventive step. The Delhi High Court set aside each ground:

Section 3(d). The Court held that Section 3(d), which addresses certain new form of a known substance to demonstrate enhanced therapeutic efficacy, is directed at salt forms, polymorphs, and derivatives of a single known compound — not at combinations of two or more independent active pharmaceutical ingredients (APIs). The court further emphasised the need for the Controller specifically identify the “known compound” and analyse the enhanced therapeutic efficacy data, even if Section 3(d) is invoked adequately.
Section 3(i). The Court held that a pharmaceutical combination claim does not automatically fall within the scope of “method of treatment” under Section 3(i) merely because the claim describes sequential administration. The Section 3(i) exclusion is directed at claims that are, in substance, methods of medical treatment — not at product claims that happen to describe how the product is administered.
Inventive step. The Court found that the Controller’s inventive step objection was not supported by prior art that disclosed the specific combination, and that the Controller had not reasoned the “motivation to combine” standard adequately.

The matter was remanded to the Controller for de novo consideration within six months, with the direction to the Controller that the application must be decided on merits, free of the earlier flawed reasoning.

The Grains Research and Development Corp v Assistant Controller ruling (23 February 2026). A separate Delhi High Court ruling earlier in 2026 held that Section 3(d) objections must be supported by independent analysis of the “known substance or process” being compared, and that the Controller must identify and reason out the specific statutory requirements. Any refusals that fails this standard will be set aside on appeal.

The Syngenta v Controller ruling (4 May 2026). In an agrochemical patent context, the Delhi High Court held that “efficacy” under Section 3(d) is not confined to therapeutic efficacy — for agrochemicals, functional and practical advantages such as enhanced stability and improved field performance can meet the efficacy threshold. The pharmaceutical heartland of Section 3(d) continues to apply the therapeutic-efficacy standard established in Novartis AG v Union of India (2013).

What foreign pharma counsel should do. The practical consequences for foreign pharma counsel are three. For combination patent applications in prosecution before the Indian Patent Office, respond to Section 3(d) objections by framing the claim as a combination of independent APIs — Array BioPharma is the leading precedent against the application of Section 3(d) to such combinations. For claims that describe sequential or combination administration, resist any Section 3(i) method-of-treatment objection by distinguishing product claims from treatment-method claims — again, Array BioPharma applies. For granted Indian patents where enforcement is contemplated, the Array BioPharma framework strengthens the position in validity challenges.

Section 2: What is the Supreme Court’s pending challenge to the 20-year patent term calculation?

Bottom line. The Supreme Court is examining a constitutional challenge to the statutory provision calculating India’s 20-year patent term from the filing date, rather than the grant date. In September 2026, a bench of Justices Narasimha and Aradhe in Gunjan Sinha@ Kanishk Sinha v. The Union of India (SLP (C) Diary No. 43127/2026), issued notice on a special leave petition arising from a seven-year patent prosecution delay and appointed an amicus curiae Kruttika Vijay, to assist the Court. If the Court accepts the challenge, the effective life of every Indian pharma patent that suffered prosecution delay would extend.

The constitutional question. The challenge contends that the current statutory framework — under which the 20-year term runs from the date of filing — effectively strips the patent holder of the years lost to administrative delay in the Patent Office. The petition argues this violates Article 14 (equality before the law) and Article 300A (property rights) of the Constitution of India where the Patent Office is itself the cause of the lost years.

Why this matters for pharma specifically. Pharmaceutical patents are the single most delay-sensitive category of Indian patents. The typical Indian pharma patent takes 5-10 years from filing to grant, often longer where Section 3(d) or Section 3(i) objections prolong prosecution. A foreign pharma major with a 10-year grant delay effectively has 10 years of enforceable patent life, not 20. If the Supreme Court accepts the challenge, the available remedy — most likely a term-extension mechanism tied to prosecution delay — would materially increase the realised value of every Indian pharma patent that suffered delay.

Timeline and status. Supreme Court notice issued; amicus curiae appointed; the matter is at a pre-merits stage. A final ruling is unlikely before Q2-Q3 2027, but foreign pharma counsel should monitor the hearing calendar and the amicus curiae’s submissions as these will shape the eventual framework.

What foreign pharma counsel should do. For foreign pharma clients with Indian patents that suffered material prosecution delay (five years or more between filing and grant), the sensible step is to document the delay chronology now — Patent Office hearings, First Examination Report dates, response times, pre-grant opposition history. If the Supreme Court ultimately grants a term-extension framework, that documentation will be the evidentiary basis of any extension application.

Section 3: How is pharma trademark enforcement operating in India in Q3-Q4 2026?

Bottom line. The Delhi High Court applies a heightened-caution line to pharmaceutical trademarks under the framework established in Cadila Healthcare v Cadila Pharmaceuticals (2001), with Q3 2026 rulings showing both sides of how the framework operates. Two Delhi High Court decisions illustrate different aspects of pharmaceutical trademark enforcement. The ex parte ad interim injunction in Nava Healthcare Pvt Ltd v Antex Pharma Pvt Ltd (CS (COMM) 739/2026, Justice Jyoti Singh, 24 July 2026) restrained the defendant from manufacturing or marketing products under allegedly deceptively similar marks and trade dress. The Hahnemann DIGESTO PLUS Division Bench ruling (FAO (COMM) 182/2026, Justice Kameswar Rao and Justice Manmeet Pritam Singh Arora, 20 August 2026) held that “DIGESTO” is descriptive and common to the trade — descriptive-term overlap does not sustain deceptive similarity, even in the pharma context.

The Cadila Healthcare framework. The 2001 Supreme Court ruling in Cadila Healthcare v Cadila Pharmaceuticals established that pharmaceutical trademarks warrant heightened judicial caution because confusion between pharmaceutical marks can cause patient harm. The Court set out factors including the nature of the goods, class of purchasers, mode of purchasing, and the health risk if the wrong product is dispensed. The heightened-caution standard remains the touchstone for pharmaceutical trademark enforcement in India.

The Nava Healthcare application (24 July 2026). Nava Healthcare Pvt Ltd, the registered proprietor of trademarks including HAIRFUL and UDIVIN (and related packaging and trade dress), filed a trademark and copyright infringement suit against Antex Pharma Pvt Ltd and a co-defendant. The Delhi High Court (Justice Jyoti Singh) granted an ex parte ad interim injunction restraining the defendants from manufacturing, selling, offering for sale, advertising, or promoting pharmaceutical products under trademarks, trade dress, packaging, or artistic works alleged to be deceptively similar to Nava’s registered rights. The suit is at the interim stage; final merits are yet to be tried after a contested hearing. The specific mark pairings on which the injunction was granted, and the application of the Cadila Healthcare heightened-caution line in the Court’s reasoning, require primary-source verification against the order text.

The Hahnemann DIGESTO PLUS ruling (early September 2026). A Division Bench of the Delhi High Court (Justice Kameswar Rao and Justice Manmeet Pritam Singh Arora) rejected an appeal by Hahnemann Scientific Laboratory India Pvt Ltd against Meera Rastogi (trading as Hahnemann Memorial Laboratory) in a dispute concerning the “DIGESTO PLUS” mark. The Court held that “DIGESTO” is descriptive and common to the trade — meaning that competing products using the “DIGESTO” prefix for digestive products cannot be enjoined on the basis of deceptive similarity alone. The descriptive-term limitation applies even within the pharmaceutical trademark context, where the Cadila Healthcare heightened-caution standard would otherwise operate.

What foreign pharma counsel should do. For foreign pharma companies managing Indian trademark portfolios, the operational framework is that strong, distinctive, non-descriptive marks (coined terms, invented names, or marks with no descriptive relationship to the therapeutic class) enjoy the full benefit of the Cadila Healthcare heightened-caution line. Marks that incorporate descriptive terms, generic prefixes or terminologies, or therapeutic-class references face the DIGESTO PLUS limitation and may struggle to sustain injunctive relief against third-party marks using the same descriptive element. A pharma trademark portfolio audit at the mark-selection stage should prioritise distinctiveness over descriptive informativeness. For enforcement actions already contemplated, the Nava Healthcare framework shows that where the marks are registered and the trade-dress similarity is clear, ex parte ad interim relief remains obtainable at the Delhi High Court on a prima facie case.

Section 4: Does India now recognise patent linkage between patent status and drug marketing approval?

Bottom line. No. India does not recognise patent linkage — the regulatory mechanism (used in several foreign jurisdictions) under which drug marketing approval is automatically refused, suspended or deferred because the proposed product may be covered by an existing patent automatically refused, suspended or deferred because the proposed product may be covered by an existing patent. The Delhi High Court’s position, consistently applied since the Bayer v Union of India ruling (2010), remains that patent enforcement and drug regulatory approval operate as separate regimes. Recent 2026 development in Maxford Healthcare v Union of India (W.P. (C) 6845/2025, Justice Purushaindra Kumar Kaurav, 13 March 2026) have not altered this position.

The Bayer v Union of India framework. The Delhi High Court’s 2010 ruling (upheld on appeal) held that reading patent linkage into Indian law would require legislative action, not judicial interpretation. The CDSCO (the Central Drugs Standard Control Organisation — India’s drug regulator) does not maintain a patent register analogous to the US FDA Orange Book. Patent holders enforce their patents through the civil courts; drug approval proceeds independently.

Q3-Q4 2026 development reinforce the position.

Maxford Healthcare v Union of India (2026: DHC: 3690) addressed CDSCO’s power to review state-issued Fixed Dose Combination (FDC) licences. The Court upheld CDSCO’s centralised review authority but did not create any patent-linkage mechanism.

What foreign pharma counsel should do. For foreign pharma clients considering Indian patent enforcement strategy, the absence of linkage means that civil patent proceedings (injunctions under Section 108 of the Patents Act, 1970) remain the operative enforcement route. Marketing approvals granted to generic competitors do not themselves infringe; manufacture and sale of the patented product by the approvee is what triggers enforcement. The Indian framework favours litigation-based enforcement over regulatory gatekeeping.

Section 5: What is the current state of compulsory licensing in Indian pharma?

Bottom line. Compulsory licensing under Section 84 of the Patents Act, 1970 remains available in India after three years from grant, on three statutory grounds — the reasonable requirements of the public not being met, the invention not being available at a reasonably affordable price, or the invention not being worked in India. However, the practical operation of Section 84 has become narrower post Natco v Bayer (Nexavar, 2012). Later applications — including compulsory licence applications on Dasatinib and Herceptin (trastuzumab) — have been refused. No new compulsory licence has been granted in Q3-Q4 2026 on a pharmaceutical product.

The Natco v Bayer precedent. The 2012 case on compulsory licence over Bayer’s anti-cancer drug Nexavar (Sorafenib Tosylate) remains the leading example of Section 84 operating against a foreign pharma major. The licence was set at approximately ₹8,800 per month compared to Bayer’s substantially higher price. The ruling established that Section 84 is a live provision, not a dead letter.

Why later applications have struggled. Section 84(6) requires the Controller to weigh several factors including the nature of the invention, the time elapsed since grant, measures taken by the patentee or its licensees to use the invention, the applicant’s ability to work the invention to public advantage, and the applicant’s efforts to secure a voluntary licence first. Where applicants have sent letters requesting voluntary licences and failed to pursue negotiation substantively, the Controller has treated this as insufficient to establish the required “efforts.” The jurisprudence has also raised the evidentiary burden on affordability — applicants must demonstrate not just high foreign-market prices but the specific gap between the Indian price and genuine Indian patient affordability.

Sections 92 and 92A — emergency and export licensing. Section 92 permits compulsory licensing in national emergencies or circumstances of extreme urgency. Section 92A permits compulsory licensing for manufacturing and export of patented pharmaceutical products to countries lacking manufacturing capacity. No relevant Section 92 or Section 92A activity occurred during Q3–Q4 2026.

What foreign pharma counsel should do. For foreign pharma companies holding Indian patents on commercially significant pharmaceutical products, the baseline risk assessment is: three-year post-grant exposure to Section 84 applications; evidentiary vulnerability on affordability where the Indian price materially exceeds comparable Indian income levels; and procedural vulnerability where voluntary licence requests from Indian generics have not been engaged with substantively. A proactive strategy — voluntary licensing to one or more credible Indian partners, transparent pricing for defined patient segments, or patient access programmes — mitigates both the Section 84 risk and the reputational cost of refusing requests.

Section 6: How does IPR customs enforcement work for pharma trademark and patent protection?

Bottom line. The Intellectual Property Rights (Imported Goods) Enforcement Rules, 2007 (as amended by the 2018 Amendment Rules) permit the Customs authority to suspend clearance of goods imported into India where they are suspected to infringe a trademark, copyright, design, or GI (geographical indication) recorded with the CBIC (Central Board of Indirect Taxes and Customs). The 2018 amendments removed patents from the scope — Customs enforcement of patent rights operates through separate seizure and confiscation mechanisms under Section 11 and Section 111 of the Customs Act, 1962. For foreign pharma trademark holders, Customs recordation is a cost-effective complement to court-based enforcement.

The recordation mechanism. Rights holders record their trademark, copyright, design, or GI on the Indian Customs IPR Recordation portal (ICeR), administered by the Central Board of Indirect Taxes and Customs(CBIC), supplying evidence of validity, a representation of the mark, and a bond with security. Once recorded, Customs officers at Indian ports can suspend clearance of goods matching the recorded IPR.

The procedural steps.

A notice of suspension is issued to the importer and the rights holder, stating the reasons for suspension and the suspected IPR infringement.
The rights holder has 10 working days (extendable by a further 10) to join proceedings and request confiscation.
If the rights holder joins and provides the required bond, Customs can confiscate the goods under Section 111 of the Customs Act, 1962.
If the rights holder does not join within the window, the suspended goods are released to the importer.

The 2018 patents exclusion. The 2018 Amendment Rules (Notification No. 56/2018-Customs (N.T.), dated 22 June 2018) removed patents from the recordation framework. Patent-based Customs enforcement now proceeds through court-ordered seizures or through Section 11 prohibition notifications on specific products — more cumbersome than the pre-2018 position but still available.

What foreign pharma counsel should do. For foreign pharma companies with branded formulations entering India through import channels, Customs recordation of the trademark provides a border-stage enforcement layer that is substantially cheaper than court-based enforcement. For patent-based enforcement, counsel should model the Section 11 prohibition route or court-ordered seizure through civil infringement proceedings — Customs recordation is not available.

What foreign pharma counsel should audit before Q1 2027

Section 3(d) prosecution audit. For every pending Indian pharma patent application, confirm that responses to Section 3(d) objections explicitly identify the base compound, articulate enhanced therapeutic efficacy data, and address the inventive step framework independently.
Delay-chronology documentation. For granted Indian patents that suffered material prosecution delay (five years or more), document the delay chronology now — Patent Office hearings, First Examination Report dates, pre-grant opposition history. If the Supreme Court term-extension challenge succeeds, this documentation becomes the evidentiary basis for extension applications.
Pharma trademark portfolio audit. For every Indian pharma trademark, assess whether the mark is distinctive (strong against Cadila Healthcare framework) or descriptive (vulnerable to the DIGESTO PLUS limitation). Where descriptive terms dominate the mark, consider portfolio refresh.
Compulsory licensing risk assessment. For commercially significant pharma patents past the three-year threshold, run the three-ground Section 84 risk assessment — reasonable requirement, affordability, working in India. Consider voluntary licensing options proactively.
Customs recordation of trademark portfolios. For branded Indian pharma products with import channels, record trademarks with the Indian Customs IPR Recordation portal. The one-time recordation cost is substantially lower than court-based enforcement.
Pending Supreme Court matters watch list. Monitor the patent term constitutional challenge (notice issued September 2026); the Philips SEP matter (SC stay July 2026); and the CCI jurisdiction-over-patents question (pending). Any of these could reshape the Indian pharma IP landscape in 2027.

FAQ — Foreign Pharma Counsel Questions on Indian Pharma IP

Q: Is a Section 3(d) rejection by the Indian Patent Office appealable, and what is the standard of review?

Yes. Section 3(d) rejections by the Controller of Patents are appealable to the High Court exercising its appellate jurisdiction over the Patent Office. The Delhi High Court set aside the Section 3(d) refusal in Array BioPharma v Deputy Controller (23 July 2026, 2026:DHC:5856) where the Controller invoked Section 3(d) against a combination of independent active pharmaceutical ingredients without identifying any “known compound.” The Court held that Section 3(d) does not apply to combinations of independent APIs — a materially different holding from the standard “enhanced therapeutic efficacy” framework that applies to new forms of a single known substance.

Q: Does India calculate patent term from the filing date or the grant date?

Currently from the filing date — 20 years from the date of filing of the complete specification. However, the Supreme Court issued notice in September 2026 on a special leave petition challenging the constitutional validity of this calculation, where the applicant lost seven years to Patent Office administrative delay. The question is at a pre-merits stage; a final ruling is unlikely before Q2-Q3 2027.

Q: Is patent linkage recognised in India for pharmaceutical products?

No. India does not recognise patent linkage — the regulatory mechanism tying drug marketing approval to patent status. CDSCO (the drug regulator) grants marketing approvals independently of patent status, consistent with the Delhi High Court’s position in Bayer v Union of India (2010). Patent enforcement remains a civil-court matter under Section 108 of the Patents Act, 1970.

Q: How does the Indian compulsory licensing framework operate under Section 84?

Section 84 permits a compulsory licence after three years from grant, on three grounds — the reasonable requirements of the public not being met, the invention not being available at a reasonably affordable price, or the invention not being worked in India. The Controller weighs factors in Section 84(6) including the applicant’s efforts to secure a voluntary licence first. The leading precedent remains Natco v Bayer (Nexavar, 2012). Later applications have struggled to meet the evidentiary standards.

Q: What is the pharmaceutical trademark heightened-caution line in India?

Established in Cadila Healthcare v Cadila Pharmaceuticals (2001), the pharmaceutical heightened-caution line requires Indian courts to apply stricter scrutiny to pharmaceutical trademark disputes because confusion between pharmaceutical marks can cause patient harm. The 2026 line of authority — including Nava Healthcare v Antex Pharma (Delhi HC, 24 July 2026), where an ex parte ad interim injunction was granted on a prima facie case — continues to apply the framework robustly where marks are registered and trade-dress similarity is clear. The Hahnemann DIGESTO PLUS Division Bench ruling (September 2026) carves out the descriptive-term limitation — competing products using a common descriptive prefix cannot be enjoined on deceptive similarity alone.

Q: Can foreign pharma trademark holders use Indian Customs enforcement to stop infringing imports?

Yes, for trademarks (and for copyright, designs, and GIs). The IPR (Imported Goods) Enforcement Rules, 2007 (as amended in 2018) permit recordation of trademarks with the CBIC. Once recorded, Customs officers at Indian ports can suspend clearance of suspected infringing goods, with a 10-working-day window (extendable by 10) for the rights holder to join proceedings. Patents were removed from Customs recordation in 2018; patent-based border enforcement proceeds through separate court-ordered mechanisms.